<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189836</url>
  </required_header>
  <id_info>
    <org_study_id>ATTCK-20-03</org_study_id>
    <nct_id>NCT03189836</nct_id>
  </id_info>
  <brief_title>Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma</brief_title>
  <official_title>Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cogent Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cogent Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and&#xD;
      anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with&#xD;
      rituximab in subjects with refractory or relapsed CD20+ B cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision&#xD;
  </why_stopped>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Actual">September 21, 2020</completion_date>
  <primary_completion_date type="Actual">September 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by dose limiting toxicities (DLTs)</measure>
    <time_frame>28 days</time_frame>
    <description>Dose-limiting toxicities, MTD, incidence and severity of AEs and clinically significant abnormalities of laboratory values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of maximum tolerated dose and proposed recommended Phase 2 dose</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-lymphoma activity as measured by overall response rate</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-lymphoma activity as measured by duration of response</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-lymphoma activity as measured by progression-free survival</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-lymphoma activity as measure by overall survival</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of persistence of ACTR707 as measured by flow cytometry and qPCR</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of ACTR707 phenotype and function as measured by flow cytometry</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of inflammatory markers and cytokines/chemokines</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cytokines and Inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rituximab PK</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rituximab plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>ACTR707 in combination with rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACTR707</intervention_name>
    <description>autologous T cell product</description>
    <arm_group_label>ACTR707 in combination with rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>CD20-directed cytolytic antibody</description>
    <arm_group_label>ACTR707 in combination with rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed written informed consent obtained prior to study procedures&#xD;
&#xD;
          -  histologically-confirmed relapsed or refractory CD20+ B-cell lymphoma of one of the&#xD;
             following types, with documented disease progression or recurrence following the&#xD;
             immediate prior therapy: DLBCL (regardless of cell of origin or underlying molecular&#xD;
             genetics), MCL, PMBCL, Gr3b-FL, TH-FL (prior dx of FL before transforming to DLBCL).&#xD;
&#xD;
          -  biopsy-confirmed CD20+ expression of the underlying malignancy with disease&#xD;
             progression following immediate prior therapy&#xD;
&#xD;
          -  at least 1 measurable lesion on imaging.&#xD;
&#xD;
          -  must have received adequate prior therapy for the underlying CD20+ B-cell lymphoma,&#xD;
             defined as an anti-CD20 mAb in combination with an anthracycline-containing&#xD;
             chemotherapy regimen (i.e. chemo-immunotherapy) and at least one of the following:&#xD;
&#xD;
               -  biopsy-proven refractory disease after frontline chemo-immunotherapy&#xD;
&#xD;
               -  relapse within 1 year from frontline chemo-immunotherapy and ineligible for&#xD;
                  autologous hematopoietic stem cell transplant (auto-HSCT)&#xD;
&#xD;
               -  for subjects with DLBCL, PMBCL, and Gr3b-FL: relapsed or refractory disease&#xD;
                  following at least 2 prior regimens or following an auto-HSCT&#xD;
&#xD;
               -  for subjects with TH-FL: relapsed or refractory disease following at least 2&#xD;
                  prior regimens or following an auto-HSCT. At least 1 prior regimen with an&#xD;
                  anti-CD20 mAb in combination with chemotherapy is required following documented&#xD;
                  transformation&#xD;
&#xD;
               -  for subjects with MCL (confirmed with cyclin D1 expression or evidence of&#xD;
                  t(11;14) by cytogenetics, fluorescent in situ hybridization (FISH) or polymerase&#xD;
                  chain reaction (PCR): relapsed or refractory disease after at least 1 prior&#xD;
                  regimen with chemo-immunotherapy (prior auto-HSCT is allowable)&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
          -  life expectancy of at least 6 months&#xD;
&#xD;
          -  platelet count greater than 50,000/ÂµL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known active central nervous system (CNS) involvement by malignancy.&#xD;
&#xD;
          -  prior treatment as follows:&#xD;
&#xD;
               -  alemtuzumab within 6 months of enrollment&#xD;
&#xD;
               -  fludarabine, cladribine, or clofarabine within 3 months of enrollment&#xD;
&#xD;
               -  external beam radiation within 2 weeks of enrollment&#xD;
&#xD;
               -  mAb (including rituximab) within 2 weeks of enrollment&#xD;
&#xD;
               -  other lymphotoxic chemotherapy (including steroids except as below) within 2&#xD;
                  weeks of enrollment&#xD;
&#xD;
               -  experimental agents within 3 half-lives prior to enrollment, unless progression&#xD;
                  is documented on therapy&#xD;
&#xD;
          -  clinically significant cardiac disease&#xD;
&#xD;
          -  clinically significant active infection&#xD;
&#xD;
          -  clinically significant CNS disorder&#xD;
&#xD;
          -  clinical history, prior diagnosis, or overt evidence of autoimmune disease&#xD;
&#xD;
          -  known bone marrow involvement due to underlying malignant disease, in dose-escalation&#xD;
             phase only&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Sachs, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cogent Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Bone and Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD20+</keyword>
  <keyword>B cell</keyword>
  <keyword>ACTR</keyword>
  <keyword>ACTR707</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>T cell</keyword>
  <keyword>T cell product</keyword>
  <keyword>adoptive T cells</keyword>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

